Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Lancet Oncol. 2020 Aug 28;21(10):1317–1330. doi: 10.1016/S1470-2045(20)30452-6

Figure 3.

Figure 3.

Subgroup analysis of progression-free survival. Shown are the results of an analysis of progression-free survival in specific subgroups based on stratified Cox proportional hazards regression. The International Staging System (ISS) disease stage, based on serum β2-microglobulin and albumin levels, consists of three stages. Cytogenetics represent conventional metaphase karyotype analysis. Presence of deletion 13q and t(4;14) were determined on fluorescence in situ hybridization performed on tumor cells at baseline. Eastern Cooperative Oncology Group (ECOG) performance status is scored on a scale from 0 to 5, with 0 indicating no symptoms and higher scores indicating increasing disability. The subgroup analysis for the type of multiple myeloma was performed on data from patients who had measurable disease in serum.